Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5% - Should You Buy?

Key Points

• Shares jumped 8.5% to about $4.48 on Wednesday; Wall Street sentiment is a “Moderate Buy” with a consensus target of $11.09 and several firms (Needham, Raymond James, Wells Fargo) recently raising price targets.
• The company beat quarterly estimates with EPS of ($0.08) and revenue of $5.49M, but remains unprofitable with a negative ROE and a net margin of -1,144.97%, despite very strong liquidity (quick/current ratio 12.23).
• Insiders have sold a total of 598,623 shares in the past 90 days (including CFO and CEO transactions), while institutional investors own roughly 77.7% of the stock.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) shares traded up 8.5% on Wednesday . The company traded as high as $4.53 and last traded at $4.4810. 1,028,076 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 2,727,517 shares. The stock had previously closed at $4.13.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TSHA. Needham & Company LLC lifted their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, March 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Raymond James Financial reissued a "strong-buy" rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, January 5th. Finally, Wall Street Zen upgraded shares of Taysha Gene Therapies from a "sell" rating to a "hold" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.09.

Taysha Gene Therapies Stock Performance

The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The stock has a fifty day moving average price of $4.61 and a two-hundred day moving average price of $4.58. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -13.37 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. Taysha Gene Therapies had a negative return on equity of 56.64% and a negative net margin of 1,144.97%.The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. As a group, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other news, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the sale, the chief financial officer directly owned 1,443,786 shares in the company, valued at $6,655,853.46. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the company's stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $190,448.32. Following the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. The trade was a 1.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 598,623 shares of company stock worth $2,822,188 over the last ninety days. 3.78% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. B Group Inc. increased its stake in Taysha Gene Therapies by 43.4% in the second quarter. B Group Inc. now owns 1,800,556 shares of the company's stock valued at $4,159,000 after purchasing an additional 545,000 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $1,890,000. GSA Capital Partners LLP increased its stake in shares of Taysha Gene Therapies by 969.0% during the 3rd quarter. GSA Capital Partners LLP now owns 477,749 shares of the company's stock valued at $1,562,000 after acquiring an additional 433,059 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at about $6,207,000. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $462,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.